Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100899 | 0.91 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL15090575 | 0.91 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL15090722 | 0.90 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL15090520 | 0.89 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL15090463 | 0.89 | HSD11B1 (0.42) | HSD11B1LYNSYKTYRO3 | |
| SCHEMBL15090566 | 0.89 | HSD11B1 (0.47) | HSD11B1TYRO3 | |
| SCHEMBL15090629 | 0.86 | HSD11B1 (0.42) | HSD11B1TYRO3 | |
| SCHEMBL15090592 | 0.86 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL15090474 | 0.86 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL15090496 | 0.86 | HSD11B1 (0.46) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | claimed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | claimed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | claimed |
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | HSD11B1 583/4885LYN 2213/4885SYK 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.